Gary A. Lyons was named Rigel’s Chairman of the Board in November 2014, having joined us as a director in October 2005. Mr. Lyons also serves as a member of the board of directors of Neurocrine Biosciences, Inc., where he served as Chief Executive Officer from 1993 until 2008. In addition, Mr. Lyons serves on the boards of directors of Eledon Pharmaceuticals, Inc. and Brickell Biotech, Inc., and is chairman of the board at Travere Therapeutics, Inc. He served on the board of directors of PDL BioPharma, Inc., from July 2008 until he resigned in December 2008 to join the board of directors of Facet Biotech Corporation following Facet’s spin-off from PDL, and served on the board of directors there until Facet’s acquisition by Abbott Laboratories in 2010. Mr. Lyons also served on the board of directors of Cytori Therapeutics, Inc. From 1983 to 1993, he held a number of management positions at Genentech, including Vice President of Business Development and Vice President of Sales, and also served as a member of Genentech’s Executive Committee. Mr. Lyons was responsible for international licensing, acquisitions and partnering for Genentech’s Corporate Venture Program and had operating responsibility for Genentech’s two subsidiaries, Genentech Canada, Inc. and Genentech Limited (Japan). He holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.
President and Chief Executive Officer
Raul R. Rodriguez is the President and Chief Executive Officer of Rigel and serves on our Board of Directors. Before being named CEO in November 2014, Mr. Rodriguez held management positions of increasing responsibility within the company, most recently serving as President and Chief Operating Officer since June 2010. He joined Rigel as Vice President, Business Development in April 2000. Prior to his employment at Rigel, Mr. Rodriguez was Senior Vice President, Business Development and Operations for Ontogeny, Inc. (now Curis); Executive Director, Business Development and Market Planning for Scios, Inc. (now J&J); and held various positions at G.D. Searle & Company (now Pfizer). After earning his A.B. from Harvard College, Mr. Rodriguez went on to earn his Masters of Public Health at the University of Illinois and his M.B.A. at the Stanford Graduate School of Business.
Chief Executive Officer, CharlestonPharma, LLC
Bradford S. Goodwin joined us as a director in January 2007. Mr. Goodwin most recently was CEO of CharlestonPharma, LLC. Mr. Goodwin’s prior public company board service includes NeurogesX, Facet Biotech Corporation (now Abbott Laboratories), PDL BioPharma, CoTherix, Inc. (now Actelion Pharmaceuticals), and Novacea, Inc. From 2001 to 2006, he was Chief Executive Officer and director of Novacea, Inc. a publicly held biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for cancer. Prior to Novacea, Mr. Goodwin was President, Chief Operating Officer and Founder of Collabra Pharma, a company focused on pharmaceutical product licensing and development. Before starting Collabra, he held various senior executive positions with Genentech, Inc., including Vice President of Finance. After becoming a CPA while working as an auditor at PricewaterhouseCoopers, he served on expert advisory committees of the American Institute of Certified Public Accountants, the Financial Accounting Standards Board and the International Accounting Standards Board. Mr. Goodwin holds a B.S. in Business Administration from the University of California, Berkeley.
Chief Medical Officer, CytomX Therapeutics
Alison L. Hannah, M.D. joined us as a director in May 2021. Dr. Hannah brings over three decades of pharmaceutical industry experience to Rigel, including a deep knowledge of clinical development strategy in hematology and oncology with a focus on molecularly targeted therapies. Dr. Hannah currently serves as Chief Medical Officer for CytomX Therapeutics, a clinical-stage biopharmaceutical company developing conditionally activated therapies to treat cancer. Prior to joining CytomX, Dr. Hannah served as a consultant to nearly 30 pharmaceutical and biotechnology companies directing the development of investigational cancer therapies. In this capacity, Dr. Hannah has successfully filed over 40 regulatory applications for First-in-Human clinical testing and has played significant roles in the broad marketing approval of multiple anticancer therapeutics (including talazoparib, enzalutamide, defibrotide, carfilzomib, as well as tyrosine kinase inhibitors sunitinib and toceranib), including extensive experience interacting with global health and regulatory authorities. Earlier in her career, Dr. Hannah held the role of Senior Medical Director at SUGEN, Inc. (acquired by Pharmacia & Upjohn, now Pfizer) where she had oversight of clinical development, clinical operations, and pharmacovigilance, specializing in the development of tyrosine kinase inhibitors, including sunitinib (SUTENT) approved for the treatment of kidney cancer and imatinib-refractory gastrointestinal stromal tumors. Dr. Hannah began her career at Quintiles, a global contract research organization, where she specialized in overseeing early to registrational-stage oncology clinical trials. Dr. Hannah currently serves on the board of NeoGenomics, a publicly traded cancer diagnostic company. Dr. Hannah received her B.A. in biochemistry and immunology from Harvard University and her M.D. from the University of Saint Andrews.
Advisor to the Board of Directors, Urovant Sciences
Keith A. Katkin joined us as a director in June 2015. Mr. Katkin is currently advisor to the board of directors of Urovant Sciences, a global biopharmaceutical company focused on developing novel therapies for urologic conditions. Mr. Katkin served as the CEO and a member of the board of directors of Urovant from its founding in 2017 until March of 2020. Mr. Katkin previously served as President and Chief Executive Officer of Avanir Pharmaceuticals from 2007 to 2016, until its acquisition by Otsuka Pharmaceutical Co. Mr. Katkin joined Avanir in July of 2005 as the Sr. Vice President of Sales and Marketing and a member of Avanir’s executive management team, and served on their board of directors from 2007 to 2016. Mr. Katkin was responsible for creating and executing the plan that led to the approval of Nuedexta, the growth of the company to commercial success, and the acquisition of the company by Otsuka Pharmaceutical Co. in January 2015. Prior to joining Avanir, Mr. Katkin served as the Vice President, Commercial Development for Peninsula Pharmaceuticals, playing a key role in the concurrent initial public offering and ultimate sale of the company to Johnson and Johnson. Additionally, Mr. Katkin’s employment experience includes leadership roles at InterMune, Amgen and Abbott Laboratories. Mr. Katkin is currently a member of the board of directors of Syndax Pharmaceuticals, Inc., and is chairman of the board of directors of Eledon Pharmaceuticals, Inc. Mr. Katkin has an M.B.A. from the Anderson School at UCLA and earned his B.S. in Business and Accounting from Indiana University. Mr. Katkin became a licensed certified public accountant in 1995.
Senior Vice President, Clinical Development, Nektar Therapeutics
Brian L. Kotzin, M.D., joined us as a director in August 2017. A board-certified rheumatologist and internist, Dr. Kotzin is currently Interim Chief Medical Officer and Head, Clinical Development at Nektar Therapeutics. He has been Senior Vice President, Clinical Development at Nektar Therapeutics since April 2017. Dr. Kotzin also serves on the board of directors of Progenity, Inc. From 2004 to 2015, he was Vice President, Global and Clinical Development and Head, Inflammation Therapeutic Area at Amgen, directing the global development efforts for product candidates in the inflammation area. Before joining Amgen, Dr. Kotzin was the head of Clinical Immunology in the Department of Medicine and director of the Autoimmunity Center of Excellence at the University of Colorado Health Sciences Center in Denver. Dr. Kotzin has won numerous honors, including elected “Master” of the American College of Rheumatology, the Kirkland Scholar Award for Lupus Research, the Henry Claman Chair in Clinical Immunology, the Gretchen Kramer Award for Outstanding Contributions to Medicine, and Chairmanship of the National Institutes of Health Autoimmunity Centers of Excellence. He earned his medical degree from Stanford and undergraduate degree in mathematics from the University of Southern California.
Chief Executive Officer, Cerium Pharmaceuticals
Gregg A. Lapointe, CPA, MBA, joined us as a director in November 2017. Mr. Lapointe is currently the chief executive officer and co-founder of Cerium Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases. Mr. Lapointe offers Rigel’s board nearly three decades of commercial and financial experience bringing products to market in the areas of medical devices and rare diseases. He previously served in varying roles for Sigma-Tau Pharmaceuticals, Inc., a private biopharmaceutical company, starting in 2001, including Chief Financial Officer from 2001 to 2002, Chief Operating Officer from 2003 to 2007, and Chief Executive Officer from 2008 to 2012. Mr. Lapointe led the effort to transform Sigma-Tau Pharmaceuticals from a small specialty dialysis company into a global leader in the development and commercialization of medicines for Rare Diseases. Mr. Lapointe also serves on the boards of directors of Soligenix, Inc. and Catabasis Pharmaceuticals Inc. He previously sat on the board of SciClone Pharmaceuticals, Inc., ImmunoCellular Therapeutics, Inc., Raptor Pharmaceuticals, Inc., Questcor Pharmaceuticals, Inc. and Cambrooke Therapeutics, Inc., among others. From 2009 to 2012, Mr. Lapointe was a member of the board of directors, and Chair of the Rare Disease Committee, of the Pharmaceutical Research and Manufacturers of America (PhRMA) in Washington, DC. He holds a Bachelor of Commerce degree from Concordia University (Montreal), a Graduate Diploma in Public Accountancy from McGill University (Montreal), an MBA from Duke University, and is a CPA (Illinois).
Managing Director, Pandect Bioventures
Walter H. Moos, Ph.D., joined us as a director in March 1997. Since October 2018, Dr. Moos has been Managing Director of Pandect Bioventures, a venture capital firm investing in therapeutics and biotechnologies. From 2017 to 2020, Dr. Moos was Chief Executive Officer of ShangPharma Innovation, Inc., a global pharmaceutical incubator investing in therapeutics and biotechnologies, where he now serves as Chairman Emeritus. He retired from his position as President of SRI Biosciences in 2016 after more than a decade at the independent nonprofit SRI International (Stanford Research Institute). From 1997 to 2004, Dr. Moos served as the Chairman and Chief Executive Officer of MitoKor, Inc., which became MIGENIX, Inc., where he was a member of the board of directors from 2004 to 2008. Prior to that, he served as a Vice President of Chiron Corp. (now Novartis), and as a Vice President at the Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Co. (now Pfizer). He has been an Adjunct Professor at the University of California, San Francisco, since 1992. He has also served on the boards of numerous private companies and several non-profit organizations and has been an advisor to a wide range of organizations in the U.S. and around the world. Dr. Moos holds an A.B. from Harvard University and a Ph.D. in Chemistry from the University of California Berkeley.
Founder & President, JWasman Advisors
Jane Wasman, joined us as a director in March 2019. Ms. Wasman is a strategic leader with approximately 25 years of experience in the biopharma industry working with both large, multinational corporations and privately held start-ups. Ms. Wasman is founder and president of JWasman Advisors. She previously served from 2004 to 2019 at Acorda Therapeutics, a biotechnology company developing and commercializing neurology therapies for Parkinson’s disease, migraine and multiple sclerosis, most recently as President, International & General Counsel. At Acorda, she led global strategic development, including long-range planning and development, as well as international expansion, and also built and led the Legal and Quality departments. Prior to joining Acorda, Ms. Wasman held various leadership positions at Schering-Plough, including Staff Vice President and Associate General Counsel. Previously, Ms. Wasman was an attorney at two global law firms and Associate Counsel for the U.S. Senate Veterans’ Affairs Committee. Ms. Wasman is Chair of the Board of Sellas Life Sciences, a public oncology-focused biotech company, as well as Chair of its Nominations & Governance Committee. She is also a member of the board of directors for Cytovia Therapeutics and Athersys. Since 2007, she has also served on the non-profit board of directors of NewYorkBIO, including its Executive Committee and as Chair of its Public Policy Committee. Ms. Wasman graduated magna cum laude from Princeton University, and earned her J.D. from Harvard Law School.